Oncology

At the Payer Exchange Summit on Oncology Payment Reform, hosted by the Community Oncology Alliance, Daniel McKellar, MD, who chairs the Commission on Cancer, insisted on meaningful feedback from the community to ensure adequate transformation of practices into a medical home.

More states cover all recommended evidence-based treatments, although many require copayments or put annual limits on care.

Olaparib, a PARP inhibitor approved for treating BRCA1/2-mutated ovarian cancer, has been found effective in treating men with metastatic, castrate-resistant prostate cancer.

The drug significantly delayed recurrence of the cancer in patients treated post surgery.

Payer—provider teams presented updates on their cost-saving pilot projects and looked to the future of these models in oncology care.

The company says the treatment will cost an average of $65,000.

The ASCO statement emphasizes patient-centered reform that weighs-in the value of the services rendered.

A study shows too much conflicting dietary advice causes some people to tune it all out. Nuances in the report from WHO are lost on most consumers.

The vaccine, approved in Europe last week, is now awaiting approval in the United States.

A study published in the journal Cancer presents the financial impact of cancer on a survivor and his family.

This week in managed care, documents show Horizon Blue Cross Blue Shield of NJ rolled out OMNIA prior to receiving regulatory approval, 2 Harvard professors argue the merit of the annual physical, and experts weigh in on the successes and flaws of Medicare Part D.